Candonilimab

Generic Name: Candonilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2394841-59-7

Unique Ingredient Identifier: 6FYG1DS4NW

Background: Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

Indication: 用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: cadonilimab
Drug: irinotecan
Drug: Oxaliplatin
Drug: leucovorin or levoleucovorin
Drug: 5-FU

First Posted Date: 2023-05-03

Last Posted Date: 2023-11-15

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT05839470

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

Phase 2

Not yet recruiting

Conditions: Cervical Neoplasms
Uterine Cervical Neoplasms
Cancer of Cervix
Cervical Cancer
Uterine Cervical Cancer
Cancer of the Uterine Cervix

Interventions: Drug: Cadonilimab
Drug: Nab paclitaxel

First Posted Date: 2023-04-21

Last Posted Date: 2023-05-06

Lead Sponsor: Women's Hospital School Of Medicine Zhejiang University

Target Recruit Count: 58

Registration Number: NCT05824494

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Phase 2

Not yet recruiting

Conditions: Endometrial Cancer
Endometrial Adenocarcinoma

Interventions: Drug: Cadonilimab
Drug: Lenvatinib

First Posted Date: 2023-04-21

Last Posted Date: 2023-04-21

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 32

Registration Number: NCT05824481

Locations: 🇨🇳
Sun Yat-sen University Cancer Cetntre, Guangzhou, China

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: Cadonilimab
Drug: Anlotinib
Drug: Granulocyte-Macrophage Colony-Stimulating Factor

First Posted Date: 2023-04-18

Last Posted Date: 2024-04-19

Lead Sponsor: Zhongnan Hospital

Target Recruit Count: 35

Registration Number: NCT05817214

Locations: 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1

Active, not recruiting

Conditions: NSCLC Stage IV
NSCLC Stage IIIB
NSCLC Stage IIIC

Interventions: Drug: Cadonilimab
Drug: Anlotinib
Drug: Docetaxel

First Posted Date: 2023-04-18

Last Posted Date: 2024-06-17

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 50

Registration Number: NCT05816499

Locations: 🇨🇳
lejie Cao, Hefei, Anhui, China
🇨🇳
Jing Wang, Qingdao, Shandong, China
🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

and more 2 locations

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Phase 2

Recruiting

Conditions: Rectal Cancer
MSS

Interventions: Drug: Cadonilimab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2023-04-18

Last Posted Date: 2023-04-18

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 92

Registration Number: NCT05815303

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

Phase 2

Recruiting

Conditions: dMMR Colorectal Cancer

Interventions: Drug: Cadonilimab

First Posted Date: 2023-04-18

Last Posted Date: 2023-04-18

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 50

Registration Number: NCT05815290

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases

Phase 2

Not yet recruiting

Conditions: Brain Metastases
Non Small Cell Lung Cancer

Interventions: Drug: Cadonilimab

First Posted Date: 2023-04-13

Last Posted Date: 2023-11-18

Lead Sponsor: Second Affiliated Hospital of Nanchang University

Target Recruit Count: 36

Registration Number: NCT05812534

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Phase 1

Not yet recruiting

Conditions: Renal Cell Carcinoma
Non Clear Cell Renal Cell Carcinoma
First-line Treatment
Sarcomatoid Renal Cell Carcinoma

Interventions: Drug: AK104
Drug: Axitinib

First Posted Date: 2023-04-11

Last Posted Date: 2023-09-25

Lead Sponsor: Hao Zeng

Target Recruit Count: 33

Registration Number: NCT05808608

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Cadonilimab

First Posted Date: 2023-03-30

Last Posted Date: 2023-03-30

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 30

Registration Number: NCT05790200

Locations: 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy